Hong K - Search Results

1

Anti-HER2 immunoliposomes for targeted therapy of human tumors.

Park JW, Hong K, Kirpotin DB, Meyer O, Papahadjopoulos D, Benz CC. Park JW, et al. Among authors: hong k. Cancer Lett. 1997 Oct 14;118(2):153-60. doi: 10.1016/s0304-3835(97)00326-1. Cancer Lett. 1997. PMID: 9459205

2

Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.

Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. Park JW, et al. Among authors: hong k. Clin Cancer Res. 2002 Apr;8(4):1172-81. Clin Cancer Res. 2002. PMID: 11948130

3

Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.

Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Refaat Shalaby M, Shao Y, Benz CC, Marks JD. Nielsen UB, et al. Among authors: hong k. Biochim Biophys Acta. 2002 Aug 19;1591(1-3):109-118. doi: 10.1016/s0167-4889(02)00256-2. Biochim Biophys Acta. 2002. PMID: 12183061 Free article.

4

Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.

Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. Mamot C, et al. Among authors: hong k. Cancer Res. 2003 Jun 15;63(12):3154-61. Cancer Res. 2003. PMID: 12810643

5

Liposome-based approaches to overcome anticancer drug resistance.

Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW. Mamot C, et al. Among authors: hong k. Drug Resist Updat. 2003 Oct;6(5):271-9. doi: 10.1016/s1368-7646(03)00082-7. Drug Resist Updat. 2003. PMID: 14643297 Review.

6

Development of ligand-targeted liposomes for cancer therapy.

Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC. Noble CO, et al. Among authors: hong k. Expert Opin Ther Targets. 2004 Aug;8(4):335-53. doi: 10.1517/14728222.8.4.335. Expert Opin Ther Targets. 2004. PMID: 15268628 Review.

7

Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.

Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW. Mamot C, et al. Among authors: hong k. Cancer Res. 2005 Dec 15;65(24):11631-8. doi: 10.1158/0008-5472.CAN-05-1093. Cancer Res. 2005. PMID: 16357174

8

Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.

Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. Drummond DC, et al. Among authors: hong k. Cancer Res. 2006 Mar 15;66(6):3271-7. doi: 10.1158/0008-5472.CAN-05-4007. Cancer Res. 2006. PMID: 16540680

9

Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.

Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW. Kirpotin DB, et al. Among authors: hong k. Cancer Res. 2006 Jul 1;66(13):6732-40. doi: 10.1158/0008-5472.CAN-05-4199. Cancer Res. 2006. PMID: 16818648

10

Liposome-based therapy of human ovarian cancer: parameters determining potency of negatively charged and antibody-targeted liposomes.

Straubinger RM, Lopez NG, Debs RJ, Hong K, Papahadjopoulos D. Straubinger RM, et al. Among authors: hong k. Cancer Res. 1988 Sep 15;48(18):5237-45. Cancer Res. 1988. PMID: 3409248

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,794 results

Search Page

Filters